SCHEMBL30656160

SCHEMBL30656160

O=C(O)c1csc2ccc(O)cc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.52
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
CA7 P43166 2/20 0.52
CA9 Q16790 2/20 0.52
CA14 Q9ULX7 2/20 0.52
ALDH1A1 P00352 2/20 0.52
TSHR P16473 2/20 0.52
TBXAS1 P24557 2/20 0.48
ALOX5 P09917 1/20 0.47
PTGS2 P35354 1/20 0.47
HSD17B10 Q99714 1/20 0.42
CES2 O00748 1/20 0.39
POLB P06746 2/20 0.39
PTGDR Q13258 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6130731 1.00 CA12 (0.52) CA12CA1CA2CA7CA9
SCHEMBL6130739 0.85 TBXAS1 (0.48) CA12CA1CA2CA7CA9
SCHEMBL14099689 0.84 ICAM1 (0.42) CA12CA1CA2CA7CA9
Hydrochloric Acid SCHEMBL29800062 0.84 TBXAS1 (0.47) CA12CA1CA2CA7CA9
SCHEMBL2848485 0.80 MAPT (0.47) ALDH1A1TSHRTBXAS1PTGS2HSD17B10
SCHEMBL2650447 0.80 KEAP1 (0.59) CA1CA2ALDH1A1TSHRTBXAS1
SCHEMBL2082067 0.80 CYP2A6 (0.53) CA2TSHRTBXAS1HDAC3HDAC4
SCHEMBL6130727 0.80 MTNR1A (0.48) CA2ALDH1A1TBXAS1PTGDRTBXA2R
SCHEMBL5267650 0.80 CSNK2A1 (0.47) CA2ALDH1A1TBXAS1HSD17B10MEN1
SCHEMBL17103691 0.76 ALDH1A1 (0.50) ALDH1A1TBXAS1HSD17B10CES2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346569-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-11-13 US disclosed
EP-4532013-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-04-09 EP disclosed
WO-2023227697-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346569-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM4, TRPM2, TRPM6 CA12 3346/4885CA1 1855/4885CA2 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.